A
serotonin–norepinephrine–dopamine reuptake inhibitor (
SNDRI), also known as a
triple reuptake inhibitor (
TRI), is a type of
drug that acts as a combined
reuptake inhibitor of the
monoamine neurotransmitters serotonin,
norepinephrine, and
dopamine. It does this by
concomitantly inhibiting the
serotonin transporter (SERT),
norepinephrine transporter (NET), and
dopamine transporter (DAT), respectively. Inhibition of the
reuptake of these neurotransmitters increases their
extracellular concentrations and, therefore, results in an increase in
serotonergic,
adrenergic, and
dopaminergic neurotransmission.